Brooks Laboratories Limited — Important, 07-01-2025: General Updates

The Fund Raising Committee of Brooks Laboratories Limited has approved a corrigendum to the Notice of the Extra-Ordinary General Meeting (EOGM) scheduled for January 11, 2025. This revised notice addresses observations received from the stock exchanges regarding the proposed preferential issue of equity shares. Notably, the company plans to invest up to ₹47.50 crore (cr) in its joint venture, Brooks Steriscience Limited, while maintaining its 49% equity stake. Additionally, approximately ₹2.50 crore (cr) will be allocated for general corporate purposes, covering areas such as operational expenses and capital improvements. The proposed investment reinforces the company’s commitment to expanding its presence in the pharmaceutical sector, particularly through Brooks Steriscience, which manufactures critical carbapenem products. This strategic move is expected to strengthen Brooks Laboratories' operational capabilities and improve long-term shareholder value. Investors should monitor these developments closely as they may indicate enhanced growth prospects.